Health Care·Biotechnology·$351.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.33 | N/A | +0.80% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $2.33 | N/A | +0.80% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management is pleased with the EPS results and remains focused on their strategic initiatives. However, they did not provide any updates on revenue guidance.
Management expressed satisfaction with the EPS performance despite lack of revenue guidance.
They highlighted ongoing confidence in their product pipeline.
AbbVie's strong EPS performance suggests that the company is managing its costs effectively and maintaining profitability. The stock's 2.77% increase indicates positive investor sentiment following the earnings report. However, the lack of revenue guidance may lead to uncertainty about future growth prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MASTERCARD INC Class A
Oct 29, 2019